ALFA Filings
Every announcement, straight from the exchange
Every Remus Pharmaceuticals other announcement announcement on NSE and BSE, newest first, each with its own page.
Time
5 announcements with these filters
Remus Pharmaceuticals filed its Reg 76 Reconciliation of Share Capital Audit Report for Q1 FY2027. It is a routine depository-compliance certificate with no transaction or business event.
Remus Pharmaceuticals Limited submitted its compliance certificate for the financial year ended March 31, 2026, regarding the maintenance of a Structured Digital Database. Issued by Practicing Company Secretary Tapan Shah, the certificate confirms the company has captured all six required events and maintained a non-tamperable audit trail in compliance with SEBI Insider Trading regulations.
Remus Pharmaceuticals Limited submitted its Reconciliation of Share Capital Audit Report for the quarter ended March 31, 2026. The report confirms a total issued and listed capital of 1,17,84,000 equity shares, with 100% of shares held in dematerialized form across NSDL and CDSL.
Remus Pharmaceuticals Limited submitted its quarterly compliance certificate under Regulation 74(5) of SEBI Regulations for the period ended March 31, 2026. The Registrar and Share Transfer Agent, MUFG Intime India, confirmed that share certificates received for dematerialisation were processed and listed on the exchanges within prescribed timelines.
Remus Pharmaceuticals Limited informed the National Stock Exchange that it is exempt from filing quarterly Corporate Governance reports. As an SME Emerge Platform listed entity, the company fulfills non-applicability criteria under Regulation 15(2) of SEBI LODR Regulations, 2015.